A recent PLoS ONE study detected neutralizing nanobodies against SARS-CoV-2 from nanobody phage display libraries and via in vitro and ex vivo high-throughput screenings.
A recent article posted to the bioRxiv preprint server demonstrated structural underpinnings of the neutralization of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variants by 002-S21F2, an extensive SARS-CoV-2 neutralizing antibody.
Researchers evaluated the impact of virus-neutralizing antibody titers against SARS-CoV-2 knowledge on deciding the timing of booster vaccination and social behavior.